Major Depressive Disorder Clinical Trials in Boston, Massachusetts

18 studies are recruiting for major depressive disorder in Boston, Massachusetts right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Accelerated TMS for Perinatal Depression

   We are studying a treatment for depression called accelerated Transcranial Magnetic Stimulation (TMS) among pregnant and postpartum individuals. TMS is a focal, non-invasive form of brain stimulation that is cleared by the Food and Drug Administration for depression. Typically, traditional TMS invo…

   Stage

   Not phased

   Ages

   18 to 55

   Site

   Brigham and Women's Hospital, Boston, Massachusetts

   Run by

   Brigham and Women's Hospital

   See if you can join NCT06968390 on ClinicalTrials.gov

2. A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)

   X-NOVA3 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major Depressive Disorder (MDD)

   Stage

   Phase 3

   Ages

   18 to 74

   Site

   Adams Clinical Boston, Boston, Massachusetts

   Locations

   50 in total

   Run by

   Xenon Pharmaceuticals Inc.

   See if you can join NCT07076407 on ClinicalTrials.gov

3. NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

   The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Neurocrine Clinical Site, Boston, Massachusetts

   Locations

   39 in total

   Run by

   Neurocrine Biosciences

   See if you can join NCT06911112 on ClinicalTrials.gov

4. A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)

   A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Major Depressive Disorder - Ascend

   Stage

   Phase 3

   Ages

   18 to 74

   Site

   Adams Clinical Boston, Boston, Massachusetts

   Locations

   30 in total

   Run by

   Definium Therapeutics US, Inc.

   See if you can join NCT07592689 on ClinicalTrials.gov

5. Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder

   The goal of this clinical trial is to learn if zelquistinel works to treat depression in adults. It will also learn about the safety of zelquistinel. The main questions it aims to answer are: Does zelquistinel reduce depression scores in participants compared to participants who take a placebo (a l…

   Stage

   Phase 2

   Ages

   18 to 64

   Site

   Boston Clinical Trials, Boston, Massachusetts

   Locations

   34 in total

   Run by

   Syndeio Biosciences, Inc

   See if you can join NCT06547489 on ClinicalTrials.gov

6. A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder

   X-NOVA2 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major Depressive Disorder (MDD)

   Stage

   Phase 3

   Ages

   18 to 74

   Site

   Boston Clinical Trials Llc, Boston, Massachusetts

   Locations

   51 in total

   Run by

   Xenon Pharmaceuticals Inc.

   See if you can join NCT06775379 on ClinicalTrials.gov

7. Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

   This study will evaluate the long-term safety and tolerability of NBI-1065845 as an adjunctive treatment in participants with MDD.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Neurocrine Clinical Site, Boston, Massachusetts

   Locations

   106 in total

   Run by

   Neurocrine Biosciences

   See if you can join NCT06966401 on ClinicalTrials.gov

8. Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness

   Participants will receive Transcranial Magnetic Stimulation (TMS) at a random location in the left prefrontal cortex, excluding sites that are potentially unsafe. Extensive behavioral testing will be conducted to determine which behaviors are modulated by stimulating which circuits.

   Stage

   Phase 2

   Ages

   18 to 65

   Site

   Brigham and Women's Hospital, Boston, Massachusetts

   Locations

   2 in total

   Run by

   Brigham and Women's Hospital

   See if you can join NCT06376734 on ClinicalTrials.gov

9. Triage Survey for Psychiatry Research Eligibility

   TRIAGE-Psych is a survey study designed to assess potential participants' eligibility to screen for industry-sponsored psychiatry clinical trials.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Adams Clinical, Boston, Boston, Massachusetts

   Locations

   6 in total

   Run by

   Adams Clinical

   See if you can join NCT05800925 on ClinicalTrials.gov

10. Transcranial Near Infrared Radiation and Cerebral Blood Flow in Depression - R33

    The purpose of this research study is to determine if application of near infrared energy to the forehead can change blood flow in the brains of people with depression. Near infrared energy is like light but is not visible to the human eye.

    Stage

    Not phased

    Ages

    18 to 65

    Site

    Harvard Medical School, Boston, Massachusetts

    Locations

    3 in total

    Run by

    NYU Langone Health

    See if you can join NCT05573074 on ClinicalTrials.gov

11. Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)

    The goal of this clinical trial is to learn if ABX-002 added to an existing antidepressant treatment will benefit depression symptoms in adults with moderate to severe major depressive disorder who have had an inadequate response to their antidepressant. This is a double-blind, placebo-controlled, …

    Stage

    Phase 2

    Ages

    18 to 65

    Site

    Autobahn Site #137, Boston, Massachusetts

    Locations

    50 in total

    Run by

    Autobahn Therapeutics, Inc.

    See if you can join NCT06633016 on ClinicalTrials.gov

12. Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression

    The study will consist of a 24-week-long trial examining outcomes in patients with Major Depressive Disorder and suicidal ideation who will receive intravenous (IV) ketamine and intranasal (IN) esketamine, compared to a large sample of matched historical controls. Patients will be recruited from an…

    Stage

    Phase 4

    Ages

    18 to 70

    Site

    Massachusetts General Hospital, Boston, Massachusetts

    Run by

    Massachusetts General Hospital

    See if you can join NCT05450432 on ClinicalTrials.gov

13. Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

    The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Neurocrine Clinical Site, Boston, Massachusetts

    Locations

    18 in total

    Run by

    Neurocrine Biosciences

    See if you can join NCT06786624 on ClinicalTrials.gov

14. Targeting Specific Brain Networks to Treat Specific Symptoms in Depression

    Repetitive transcranial magnetic stimulation (rTMS) is a way of non-invasively stimulating specific brain networks and is an established treatment for Major Depressive Disorder (MDD). This proposal will reveal network mechanisms of the therapeutic effects of rTMS by investigating how stimulating ea…

    Stage

    Not phased

    Ages

    18 to 65

    Site

    Massachusetts General Hospital, Boston, Massachusetts

    Run by

    Massachusetts General Hospital

    See if you can join NCT05523817 on ClinicalTrials.gov

15. Neuroactive Steroid to Treat Depressed Mood: A Trial for People With HIV

    This study will determine the effects of pregnenolone on brain function, inflammation and depressive symptoms in people with HIV who have depression. Participants in this study will receive a pill of either pregnenolone or placebo, and can stay on their current antidepression medications. Brain ima…

    Stage

    Phase 2

    Ages

    18 to 85

    Site

    Massachusetts General Hospital, Boston, Massachusetts

    Run by

    Massachusetts General Hospital

    See if you can join NCT05570812 on ClinicalTrials.gov

16. Transcranial Direct Current Stimulation (tDCS) Neuromodulation of Executive Function Across Neuropsychiatric Populations

    In the current study, the investigators aim to understand the role of transcranial direct current stimulation (tDCS) in improving executive function across neuropsychiatric populations known to have deficits in this cognitive domain.

    Stage

    Not phased

    Ages

    18 to 65

    Site

    Massachusetts General Hospital, Boston, Massachusetts

    Run by

    Massachusetts General Hospital

    See if you can join NCT04296604 on ClinicalTrials.gov

17. A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms

    This is a randomized, double-blind, active-controlled, multi-center study to evaluate the efficacy of AXS-05, compared to bupropion, in preventing the relapse of depressive symptoms in subjects with major depressive disorder (MDD) who have responded to treatment with AXS-05.

    Stage

    Phase 4

    Ages

    18 to 65

    Site

    Clinical Research Site, Boston, Massachusetts

    Locations

    40 in total

    Run by

    Axsome Therapeutics, Inc.

    See if you can join NCT06223880 on ClinicalTrials.gov

18. Peripheral Neuroimmune Mechanisms of Hyperthermia

    The goal of this study is to examine how whole-body hyperthermia affects the thermoinflammatory profile, which includes the combined immune and heat shock response, in patients with depression and whether these changes correlate with decreased depression in individuals with Major Depressive Disorde…

    Stage

    Not phased

    Ages

    18 to 65

    Site

    Massachusetts General Hospital Depression Clinical & Research Program, Boston, Massachusetts

    Run by

    Massachusetts General Hospital

    See if you can join NCT05366270 on ClinicalTrials.gov